secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-09-24T23:59:59+00:00
Accession:  0001213900-25-090872
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics: Phase 2 stenoparib shows median overall survival >25 months for platinum-resistant ovarian cancer
--------------------------------------------------------------------------------

- Median overall survival (mOS) now exceeds 25 months, not yet formally reached, in ongoing Phase 2 trial.
- Two patients remain on therapy >24 months; one with BRCA wild-type shows benefit, typically precluded by PARP inhibitors.
- Data presented at AACR 2025 Ovarian Cancer Conference; FDA draft guidance supports OS as endpoint for approval.
- Stenoparib shows less myelotoxicity vs earlier PARP inhibitors, relevant after 2022 market withdrawal of some PARP inhibitors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390025090872/0001213900-25-090872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390025090872/ea0258492-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-090872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer